SELLAS Life Sciences Group, Inc. (SLS) Earnings History
Annual and quarterly earnings data from 2006 to 2025
Loading earnings history...
SLS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 90.0% | -4195.0% | -4130.1% |
| 2021 | 97.4% | -332.8% | -272.4% |
Download Data
Export SLS earnings history in CSV or JSON format
Free sign-in required to download data
SELLAS Life Sciences Group, Inc. (SLS) Earnings Overview
As of May 8, 2026, SELLAS Life Sciences Group, Inc. (SLS) reported trailing twelve-month net income of -$26M, reflecting +50.0% year-over-year growth. The company earned $-0.24 per diluted share over the past four quarters.
Looking at the long-term picture, SLS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2006.
SELLAS Life Sciences Group, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), ADMA ($165M net income, 28.8% margin), NKTR (-$164M net income, -297.1% margin), SLS has comparable earnings metrics. Compare SLS vs IMVT →
SLS Earnings vs Peers
Earnings metrics vs comparable public companies
SLS Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +13.0% | -$28M | $-0.25 | - | - |
| 2024 | -$31M | +17.3% | -$32M | $-0.50 | - | - |
| 2023 | -$37M | +9.6% | -$38M | $-1.34 | - | - |
| 2022 | -$41M | -99.5% | -$42M | $-2.13 | -4130.1% | -4195.0% |
| 2021 | -$21M | -23.5% | -$25M | $-1.34 | -272.4% | -332.8% |
| 2020 | -$17M | +13.1% | -$17M | $-2.11 | -881.9% | -893.8% |
| 2019 | -$19M | +30.3% | -$20M | $-10.92 | - | - |
| 2018 | -$28M | -16.5% | -$32M | $-157.72 | - | - |
| 2017 | -$24M | -0.9% | -$16M | $-521.91 | - | - |
| 2016 | -$24M | +63.1% | -$16M | $-933.13 | - | - |
See SLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLS — Frequently Asked Questions
Quick answers to the most common questions about buying SLS stock.
Is SLS growing earnings?
SLS EPS is $-0.24, with earnings growth accelerating to +50.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-26M.
What are SLS's profit margins?
SELLAS Life Sciences Group, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SLS's earnings?
SLS earnings data spans 2006-2025. The accelerating earnings trend is +50.0% YoY. Historical data enables comparison across business cycles.